Asia–Pacific Oncology Molecular Diagnostics Market Research - 2035

The Asia–Pacific oncology molecular diagnostics market size was valued at $343.31 million in 2023 and is estimated to reach $1,456.83 million by 2035, exhibiting a CAGR of 13% from 2024 to 2035. The Asia-Pacific oncology molecular diagnostics market is driven by rising cancer prevalence, increasing awareness about early diagnosis, and advancements in molecular diagnostic technologies. Government initiatives promoting healthcare infrastructure development and growing investments in research further support market growth. Additionally, the expanding adoption of precision medicine and rising demand for non-invasive diagnostic methods contribute to the market's significant growth potential.

Oncology molecular diagnostics involves the use of advanced molecular techniques to identify genetic and molecular markers associated with cancer. These diagnostics aid in early detection, precise diagnosis, and personalized treatment planning by analyzing DNA, RNA, or protein changes in cancer cells. They play a crucial role in monitoring disease progression, assessing treatment efficacy, and predicting patient outcomes, thereby improving cancer care and enabling targeted therapies tailored to individual patient profiles.

Key Takeaways

• By application, the other cancers segment was the highest contributor to the market in 2023.

• By type, the polymerase chain reaction (PCR) segment was the highest contributor to the market in 2023.
• By end user, the hospitals segment dominated the market in 2023 and is expected to continue this trend during the forecast period.

Market Dynamics

The Asia–Pacific oncology molecular diagnostics market is driven by rising prevalence of cancer, advancements in molecular diagnostics, government initiatives and funding and developing healthcare infrastructure. Factors such as lifestyle changes, aging populations, and increased exposure to carcinogens have contributed to a surge in cancer cases across the region. According to American Cancer Society, there were 19,964,811 new cancer cases in Asia-Pacific region in 2022. The growing cancer prevalence has heightened the demand for advanced diagnostic solutions that enable early detection and personalized treatment strategies. Molecular diagnostics plays a crucial role in identifying specific genetic mutations and biomarkers, offering precise diagnostic capabilities that guide targeted therapies.

In addition, advancements in molecular diagnostics are driving the growth of the oncology molecular diagnostics market in the Asia-Pacific region by enabling precise and early detection of cancer. Breakthrough technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and liquid biopsy have revolutionized cancer diagnostics, allowing for the identification of specific genetic mutations and biomarkers. According to 2024 article by National Library of Medicine, the sensitivity and accuracy for the identification of uncommon DNA copies and pattern variants have significantly increased owing to techniques such as PCR and tailored NGS. These advancements improve the accuracy of cancer diagnoses and enable the development of personalized treatment plans tailored to individual patients’ genetic profiles. Additionally, the increasing adoption of automated and high-throughput molecular diagnostic platforms enhances efficiency and scalability in clinical and research settings.

Favorable initiatives by public and private organizations play a pivotal role in driving the growth of the Asia-Pacific oncology molecular diagnostics market. Governments across the region are investing heavily in healthcare infrastructure and launching national cancer control programs to improve early detection and treatment outcomes. For instance, in 2024, women investors and philanthropists of the Women Health and Economic Empowerment Network (WHEN), announced investment of more than $100 million over the next three years, with funding targeted for cervical cancer in Southeast Asia. These funds will be working to fill essential gaps for improving the prevention, screening, diagnosis, and treatment of cervical cancer.

Additionally, private organizations are forming partnerships with government for cancer screening and treatment program which also contribute significantly in the growth of the market. For instance, in 2024, Becton Dickinson & Co. (BD) announced comprehensive investments in cervical cancer screening in the Indo-Pacific. BD is working with Obstetric and Gynecological Societies to deliver education for clinicians on cervical cancer screening best practices, with an aim of reaching over 1,200 clinicians and support staff by early 2025. Collaborative efforts, such as public-private partnerships (PPPs), are contributing significantly in the adoption of the molecular diagnosis technique.

Developing healthcare infrastructure is a significant driver for the Asia–Pacific oncology molecular diagnostics market, as many countries in the region are investing heavily in improving their healthcare systems. Governments and private entities are focusing on expanding access to advanced diagnostic tools, upgrading laboratory facilities, and implementing modern technologies to address the rising burden of cancer. This growth in infrastructure enhances the availability and quality of molecular diagnostic services, enabling earlier and more accurate cancer detection and personalized treatment planning. Additionally, the increasing establishment of specialized cancer care centers and laboratories, coupled with collaborations between local and global healthcare organizations, is fostering the adoption of cutting-edge diagnostic methods. These advancements not only improve patient outcomes but also drive demand for oncology molecular diagnostics in Asia-Pacific region.

Segmental Overview

The Asia–Pacific oncology molecular diagnostics market is segmented on the basis of application, type, end user, and country. On the basis of application, the market is divided into colorectal cancer, gastric cancer, breast cancer, lung cancer, and other cancers. As per type, the market is segmented into polymerase chain reaction (PCR), next generation sequencing (NGS), fluorescence In Situ Hybridization (FISH), spectrometry, immunohistochemistry, and others. On the basis of end user, the market is divided into hospitals, reference laboratories, and others. Country-wise, the market is analyzed across Japan, China, Australia, India, South Korea, New Zealand, Singapore, Hong Kong, Taiwan, Thailand, Vietnam, Malaysia, Indonesia, Philippines, Pakistan, Myanmar and Rest of Asia-Pacific.

By Application

The other cancers segment held the largest Asia–Pacific oncology molecular diagnostics market share in 2023. This was attributed to high prevalence of the cancer such as pancreatic cancer and ovarian cancer and heightened the need for early and accurate diagnostic solutions.

[APPLICATIONGRAPH]

By Type

The Polymerase Chain Reaction (PCR) segment held the largest Asia–Pacific oncology molecular diagnostics market share in 2023. This is attributed to its widespread adoption in cancer diagnostics. PCR is highly valued for its accuracy, sensitivity, and ability to detect minute amounts of genetic material, making it essential for early cancer detection and monitoring. The region's increasing cancer prevalence, coupled with a growing emphasis on personalized medicine, has amplified the demand for PCR-based diagnostics. Additionally, advancements in PCR technologies, such as quantitative PCR (qPCR) and digital PCR, have enhanced their efficiency and precision, further driving adoption. The expanding healthcare infrastructure and increased investment in diagnostic technologies in countries like China, India, and Japan have also supported market growth.

[TYPEGRAPH]

By End User

The hospital segment held the largest share of the Asia–Pacific oncology molecular diagnostics market in 2023. This is attributed to the fact that hospitals are primary healthcare providers and serve as the central point for diagnosing and treating cancer, offering advanced molecular diagnostic technologies to accurately detect and monitor various cancer types. These facilities are equipped with state-of-the-art laboratories and expert oncologists, enabling them to handle complex diagnostic procedures, which attracts a high volume of patients. Additionally, the rising prevalence of cancer in the region, combined with increasing awareness about early diagnosis, has driven a surge in hospital visits for molecular diagnostics. Governments across Asia-Pacific countries are also investing significantly in healthcare infrastructure, particularly in hospitals, to improve access to cutting-edge diagnostic tools. Furthermore, hospitals often collaborate with research institutions and diagnostic companies to adopt the latest innovations in oncology molecular diagnostics.

[ENDUSERGRAPH]

Competition Analysis

The major companies profiled in the Asia–Pacific oncology molecular diagnostics market report include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Danaher Corporation, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Qiagen N.V, Illumina, Inc, Sysmex, Guardant Health, Lucence, LifeStrands, and ACT Genomics.

Recent Developments in Asia–Pacific Oncology Molecular Diagnostics Industry

• In September 2023, Guardant Health, Inc announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) had approved the Guardant360 CDx liquid biopsy test as a companion diagnostic to select patients with unresectable (inoperable) advanced or recurrent non-small cell lung cancer (NSCLC) with HER2 (ERBB2) mutations that has progressed after chemotherapy for treatment with ENHERTU® (trastuzumab deruxtecan). ENHERTU is a specifically engineered HER2-directed antibody drug conjugate developed by Daiichi Sankyo.

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the Asia–Pacific oncology molecular diagnostics analysis from 2023 to 2033 to identify the prevailing market opportunities.
• Market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the Asia–Pacific oncology molecular diagnostics market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Asia–Pacific oncology molecular diagnostics market trends, key players, market segments, application areas, and market growth strategies.

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments

1.2.1.Key market players profiled in the report

1.3.Key benefits for stakeholders
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.3.1.Bargaining power of suppliers
3.3.2.Bargaining power of buyers
3.3.3.Threat of substitution
3.3.4.Threat of new entrants
3.3.5.Intensity of competitive rivalry

3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Rise in prevalence of cancer
3.4.1.2.Increase in demand for personalized medicine
3.4.1.3.Developing healthcare infrastructure

3.4.2.Restraint

3.4.2.1.High cost of molecular diagnostics tests

3.4.3.Opportunity

3.4.3.1.Government initiatives and funding

3.4.4.Impact Analysis

CHAPTER 4:ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

4.1.Overview

4.1.1.Market size and forecast (TAM)
4.1.2.Market size and forecast (SAM)

4.2.Colorectal Cancer

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by Asia-Pacific (TAM)
4.2.3.Market size and forecast, by Asia-Pacific (SAM)
4.2.4.Market share analysis, by country

4.3.Gastric Cancer

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by Asia-Pacific (TAM)
4.3.3.Market size and forecast, by Asia-Pacific (SAM)
4.3.4.Market share analysis, by country

4.4.Breast cancer

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by Asia-Pacific (TAM)
4.4.3.Market size and forecast, by Asia-Pacific (SAM)
4.4.4.Market share analysis, by country

4.5.Lung cancer

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by Asia-Pacific (TAM)
4.5.3.Market size and forecast, by Asia-Pacific (SAM)
4.5.4.Market share analysis, by country

4.6.Other cancer

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by Asia-Pacific (TAM)
4.6.3.Market size and forecast, by Asia-Pacific (SAM)
4.6.4.Market share analysis, by country

CHAPTER 5:ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE

5.1.Overview

5.1.1.Market size and forecast (TAM)
5.1.2.Market size and forecast (SAM)

5.2.Polymerase Chain Reaction (PCR)

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, for Asia-Pacific (TAM)
5.2.3.Market size and forecast, for Asia-Pacific (SAM)
5.2.4.Market share analysis, by country

5.3.Next Generation Sequencing (NGS)

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by for Asia-Pacific (TAM)
5.3.3.Market size and forecast, by for Asia-Pacific (SAM)
5.3.4.Market share analysis, by country

5.4.Fluorescence In Situ Hybridization (FISH)

5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by Asia-Pacific (TAM)
5.4.3.Market size and forecast, by Asia-Pacific (SAM)
5.4.4.Market share analysis, by country

5.5.Spectrometry

5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by Asia-Pacific (TAM)
5.5.3.Market size and forecast, by Asia-Pacific (SAM)
5.5.4.Market share analysis, by country

5.6.Immunohistochemistry (IHC)

5.6.1.Key market trends, growth factors, and opportunities
5.6.2.Market size and forecast, by Asia-Pacific (TAM)
5.6.3.Market size and forecast, by Asia-Pacific (SAM)
5.6.4.Market share analysis, by country

5.7.Other

5.7.1.Key market trends, growth factors, and opportunities
5.7.2.Market size and forecast, by Asia-Pacific (TAM)
5.7.3.Market size and forecast, by Asia-Pacific (SAM)
5.7.4.Market share analysis, by country

CHAPTER 6:ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast (TAM)
6.1.2.Market size and forecast (SAM)

6.2.Hospitals

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by Asia-Pacific (TAM)
6.2.3.Market size and forecast, by Asia-Pacific (SAM)
6.2.4.Market share analysis, by country

6.3.Reference laboratories

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by country Market size and forecast, by Asia-Pacific (TAM)
6.3.3.Market size and forecast, by Asia-Pacific (SAM)
6.3.4.Market share analysis, by country

6.4.Others

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by Asia-Pacific (TAM)
6.4.3.Market size and forecast, by Asia-Pacific (SAM)
6.4.4.Market share analysis, by country

CHAPTER 7:ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY

7.1.Market overview

7.1.1.Key market trends, growth factors, and opportunities

7.1.1.1.Japan

7.1.1.1.1.Market size and forecast, by application (TAM)
7.1.1.1.2.Market size and forecast, by application (SAM)
7.1.1.1.3.Market size and forecast, by type (TAM)
7.1.1.1.4.Market size and forecast, by type (SAM)
7.1.1.1.5.Market size and forecast, by end user (TAM)
7.1.1.1.6.Market size and forecast, by end user (SAM)

7.1.1.2.China

7.1.1.2.1.Market size and forecast, by application (TAM)
7.1.1.2.2.Market size and forecast, by application (SAM)
7.1.1.2.3.Market size and forecast, by type (TAM)
7.1.1.2.4.Market size and forecast, by type (SAM)
7.1.1.2.5.Market size and forecast, by end user (TAM)
7.1.1.2.6.Market size and forecast, by end user (SAM)

7.1.1.3.India

7.1.1.3.1.Market size and forecast, by application (TAM)
7.1.1.3.2.Market size and forecast, by application (SAM)
7.1.1.3.3.Market size and forecast, by type (TAM)
7.1.1.3.4.Market size and forecast, by type (SAM)
7.1.1.3.5.Market size and forecast, by end user (TAM)
7.1.1.3.6.Market size and forecast, by end user (SAM)

7.1.1.4.Australia

7.1.1.4.1.Market size and forecast, by application (TAM)
7.1.1.4.2.Market size and forecast, by application (SAM)
7.1.1.4.3.Market size and forecast, by type (TAM)
7.1.1.4.4.Market size and forecast, by type (SAM)
7.1.1.4.5.Market size and forecast, by end user (TAM)
7.1.1.4.6.Market size and forecast, by end user (SAM)

7.1.1.5.South Korea

7.1.1.5.1.Market size and forecast, by application (TAM)
7.1.1.5.2.Market size and forecast, by application (SAM)
7.1.1.5.3.Market size and forecast, by type (TAM)
7.1.1.5.4.Market size and forecast, by type (SAM)
7.1.1.5.5.Market size and forecast, by end user (TAM)
7.1.1.5.6.Market size and forecast, by end user (SAM)

7.1.1.6.New Zealand

7.1.1.6.1.Market size and forecast, by application (TAM)
7.1.1.6.2.Market size and forecast, by application (SAM)
7.1.1.6.3.Market size and forecast, by type (TAM)
7.1.1.6.4.Market size and forecast, by type (SAM)
7.1.1.6.5.Market size and forecast, by end user (TAM)
7.1.1.6.6.Market size and forecast, by end user (SAM)

7.1.1.7.Singapore

7.1.1.7.1.Market size and forecast, by application (TAM)
7.1.1.7.2.Market size and forecast, by application (SAM)
7.1.1.7.3.Market size and forecast, by type (TAM)
7.1.1.7.4.Market size and forecast, by type (SAM)
7.1.1.7.5.Market size and forecast, by end user (TAM)
7.1.1.7.6.Market size and forecast, by end user (SAM)

7.1.1.8.Hong Kong

7.1.1.8.1.Market size and forecast, by application (TAM)
7.1.1.8.2.Market size and forecast, by application (SAM)
7.1.1.8.3.Market size and forecast, by type (TAM)
7.1.1.8.4.Market size and forecast, by type (SAM)
7.1.1.8.5.Market size and forecast, by end user (TAM)
7.1.1.8.6.Market size and forecast, by end user (SAM)

7.1.1.9.Taiwan

7.1.1.9.1.Market size and forecast, by application (TAM)
7.1.1.9.2.Market size and forecast, by application (SAM)
7.1.1.9.3.Market size and forecast, by type (TAM)
7.1.1.9.4.Market size and forecast, by type (SAM)
7.1.1.9.5.Market size and forecast, by end user (TAM)
7.1.1.9.6.Market size and forecast, by end user (SAM)

7.1.1.10.Thailand

7.1.1.10.1.Market size and forecast, by application (TAM)
7.1.1.10.2.Market size and forecast, by application (SAM)
7.1.1.10.3.Market size and forecast, by type (TAM)
7.1.1.10.4.Market size and forecast, by type (SAM)
7.1.1.10.5.Market size and forecast, by end user (TAM)
7.1.1.10.6.Market size and forecast, by end user (SAM)

7.1.1.11.Vietnam

7.1.1.11.1.Market size and forecast, by application (TAM)
7.1.1.11.2.Market size and forecast, by application (SAM)
7.1.1.11.3.Market size and forecast, by type (TAM)
7.1.1.11.4.Market size and forecast, by type (SAM)
7.1.1.11.5.Market size and forecast, by end user (TAM)
7.1.1.11.6.Market size and forecast, by end user (SAM)

7.1.1.12.Malaysia

7.1.1.12.1.Market size and forecast, by application (TAM)
7.1.1.12.2.Market size and forecast, by application (SAM)
7.1.1.12.3.Market size and forecast, by type (TAM)
7.1.1.12.4.Market size and forecast, by type (SAM)
7.1.1.12.5.Market size and forecast, by end user (TAM)
7.1.1.12.6.Market size and forecast, by end user (SAM)

7.1.1.13.Indonesia

7.1.1.13.1.Market size and forecast, by application (TAM)
7.1.1.13.2.Market size and forecast, by application (SAM)
7.1.1.13.3.Market size and forecast, by type (TAM)
7.1.1.13.4.Market size and forecast, by type (SAM)
7.1.1.13.5.Market size and forecast, by end user (TAM)
7.1.1.13.6.Market size and forecast, by end user (SAM)

7.1.1.14.Philippines

7.1.1.14.1.Market size and forecast, by application (TAM)
7.1.1.14.2.Market size and forecast, by application (SAM)
7.1.1.14.3.Market size and forecast, by type (TAM)
7.1.1.14.4.Market size and forecast, by type (SAM)
7.1.1.14.5.Market size and forecast, by end user (TAM)
7.1.1.14.6.Market size and forecast, by end user (SAM)

7.1.1.15.Pakistan

7.1.1.15.1.Market size and forecast, by application (TAM)
7.1.1.15.2.Market size and forecast, by application (SAM)
7.1.1.15.3.Market size and forecast, by type (TAM)
7.1.1.15.4.Market size and forecast, by type (SAM)
7.1.1.15.5.Market size and forecast, by end user (TAM)
7.1.1.15.6.Market size and forecast, by end user (SAM)

7.1.1.16.Myanmar

7.1.1.16.1.Market size and forecast, by application (TAM)
7.1.1.16.2.Market size and forecast, by application (SAM)
7.1.1.16.3.Market size and forecast, by type (TAM)
7.1.1.16.4.Market size and forecast, by type (SAM)
7.1.1.16.5.Market size and forecast, by end user (TAM)
7.1.1.16.6.Market size and forecast, by end user (SAM)

7.1.1.17.Rest of Asia-Pacific

7.1.1.17.1.Market size and forecast, by application (TAM)
7.1.1.17.2.Market size and forecast, by application (SAM)
7.1.1.17.3.Market size and forecast, by type (TAM)
7.1.1.17.4.Market size and forecast, by type (SAM)
7.1.1.17.5.Market size and forecast, by end user (TAM)
7.1.1.17.6.Market size and forecast, by end user (SAM)

CHAPTER 8:COMPETITIVE LANDSCAPE

8.1.Introduction
8.2.Top winning strategies

8.2.1.Top winning strategies, by year, 2021-2024*
8.2.2.Top winning strategies, by development, 2021-2024*(%)
8.2.3.Top winning strategies, by company, 2021-2024*

8.3.Product mapping of top 10 players
8.4.Competitive dashboard
8.5.Competitive heatmap
8.6.Top player positioning

CHAPTER 9:COMPANY PROFILES

9.1.THERMO FISHER SCIENTIFIC INC.

9.1.1.Company overview
9.1.2.Key executives
9.1.3.Company snapshot
9.1.4.Operating business segments
9.1.5.Product portfolio
9.1.6.Business Performance

9.2.F. HOFFMANN-LA ROCHE LTD.

9.2.1.Company overview
9.2.2.Key executives
9.2.3.Company snapshot
9.2.4.Operating business segments
9.2.5.Product portfolio
9.2.6.Business Performance

9.3.ILLUMINA, INC.

9.3.1.Company overview
9.3.2.Key executives
9.3.3.Company snapshot
9.3.4.Operating business segments
9.3.5.Product portfolio
9.3.6.Business Performance

9.4.QIAGEN NV.

9.4.1.Company overview
9.4.2.Key executives
9.4.3.Company snapshot
9.4.4.Operating business segment
9.4.5.Product portfolio
9.4.6.Business Performance

9.5.SYSMEX CORPORATION

9.5.1.Company overview
9.5.2.Key executives
9.5.3.Company snapshot
9.5.4.Operating business segment
9.5.5.Product portfolio
9.5.6.Business Performance

9.6.AGILENT TECHNOLOGIES, INC.

9.6.1.Company overview
9.6.2.Key executives
9.6.3.Company snapshot
9.6.4.Operating business segments
9.6.5.Product portfolio
9.6.6.Business Performance
9.6.7.Key Strategic Moves and Developments

9.7.DANAHER CORPORATION

9.7.1.Company overview
9.7.2.Key executives
9.7.3.Company snapshot
9.7.4.Operating business segments
9.7.5.Product portfolio
9.7.6.Business Performance

9.8.ABBOTT LABORATORIES

9.8.1.Company overview
9.8.2.Key executives
9.8.3.Company snapshot
9.8.4.Operating business segments
9.8.5.Product portfolio
9.8.6.Business Performance

9.9.LUCENCE HEALTH INC

9.9.1.Company overview
9.9.2.Key executives
9.9.3.Company snapshot
9.9.4.Operating business segments
9.9.5.Product portfolio

9.10.GUARDANT HEALTH

9.10.1.Company overview
9.10.2.Key executives
9.10.3.Company snapshot
9.10.4.Operating business segment
9.10.5.Product portfolio
9.10.6.Key Strategic Moves and Developments

9.11.LIFESTRANDS GENOMICS PTE. LTD

9.11.1.Company overview
9.11.2.Key executives
9.11.3.Company snapshot
9.11.4.Operating business segment
9.11.5.Product portfolio

9.12.ACT GENOMICS

9.12.1.Company overview
9.12.2.Key executives
9.12.3.Company snapshot
9.12.4.Operating business segment
9.12.5.Product portfolio

9.13.SIEMENS HEALTHINEERS AG

9.13.1.Company overview
9.13.2.Key executives
9.13.3.Company snapshot
9.13.4.Operating business segments
9.13.5.Product portfolio
9.13.6.Business Performance

LIST OF TABLES

TABLE 01.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 02.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 03.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2023-2035 ($MILLION)
TABLE 04.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2023-2035 ($MILLION)
TABLE 05.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION, 2023-2035 ($MILLION)
TABLE 06.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION, 2023-2035 ($MILLION)
TABLE 07.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2023-2035 ($MILLION)
TABLE 08.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2023-2035 ($MILLION)
TABLE 09.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2023-2035 ($MILLION)
TABLE 10.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2023-2035 ($MILLION)
TABLE 11.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2023-2035 ($MILLION)
TABLE 12.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2023-2035 ($MILLION)
TABLE 13.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 14.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 15.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, FOR ASIA PACIFIC, 2023-2035 ($MILLION)
TABLE 16.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, FOR ASIA PACIFIC, 2023-2035 ($MILLION)
TABLE 17.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR NEXT GENERATION SEQUENCING, BY REGION, 2023-2035 ($MILLION)
TABLE 18.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR NEXT GENERATION SEQUENCING, BY REGION, 2023-2035 ($MILLION)
TABLE 19.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2023-2035 ($MILLION)
TABLE 20.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2023-2035 ($MILLION)
TABLE 21.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR SPECTROMETRY, BY REGION, 2023-2035 ($MILLION)
TABLE 22.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR SPECTROMETRY, BY REGION, 2023-2035 ($MILLION)
TABLE 23.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY (IHC), BY REGION, 2023-2035 ($MILLION)
TABLE 24.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY (IHC), BY REGION, 2023-2035 ($MILLION)
TABLE 25.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2023-2035 ($MILLION)
TABLE 26.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2023-2035 ($MILLION)
TABLE 27.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 28.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 29.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL, BY REGION, 2023-2035 ($MILLION)
TABLE 30.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL, BY REGION, 2023-2035 ($MILLION)
TABLE 31.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2023-2035 ($MILLION)
TABLE 32.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2023-2035 ($MILLION)
TABLE 33.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2023-2035 ($MILLION)
TABLE 34.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2023-2035 ($MILLION)
TABLE 35.JAPAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 36.JAPAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 37.JAPAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 38.JAPAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 39.JAPAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 40.JAPAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 41.CHINA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 42.CHINA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 43.CHINA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 44.CHINA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 45.CHINA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 46.CHINA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 47.INDIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 48.INDIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 49.INDIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 50.INDIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 51.INDIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 52.INDIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 53.AUSTRALIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 54.AUSTRALIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 55.AUSTRALIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 56.AUSTRALIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 57.AUSTRALIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 58.AUSTRALIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 59.SOUTH KOREA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 60.SOUTH KOREA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 61.SOUTH KOREA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 62.SOUTH KOREA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 63.SOUTH KOREA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 64.SOUTH KOREA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 65.NEW ZEALAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 66.NEW ZEALAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 67.NEW ZEALAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 68.NEW ZEALAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 69.NEW ZEALAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 70.NEW ZEALAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 71.SINGAPORE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 72.SINGAPORE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 73.SINGAPORE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 74.SINGAPORE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 75.SINGAPORE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 76.SINGAPORE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 77.HONG KONG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 78.HONG KONG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 79.HONG KONG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 80.HONG KONG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 81.HONG KONG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 82.HONG KONG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 83.TAIWAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 84.TAIWAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 85.TAIWAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 86.TAIWAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 87.TAIWAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 88.TAIWAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 89.THAILAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 90.THAILAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 91.THAILAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 92.THAILAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 93.THAILAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 94.THAILAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 95.VIETNAM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 96.VIETNAM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 97.VIETNAM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 98.VIETNAM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 99.VIETNAM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 100.VIETNAM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 101.MALAYSIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 102.MALAYSIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 103.MALAYSIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 104.MALAYSIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 105.MALAYSIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 106.MALAYSIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 107.INDONESIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 108.INDONESIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 109.INDONESIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 110.INDONESIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 111.INDONESIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 112.INDONESIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 113.PHILIPPINES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 114.PHILIPPINES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 115.PHILIPPINES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 116.PHILIPPINES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 117.PHILIPPINES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 118.PHILIPPINES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 119.PAKISTAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 120.PAKISTAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 121.PAKISTAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 122.PAKISTAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 123.PAKISTAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 124.PAKISTAN ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 125.MYANMAR ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 126.MYANMAR ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 127.MYANMAR ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 128.MYANMAR ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 129.MYANMAR ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 130.MYANMAR ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 131.REST OF ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 132.REST OF ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 ($MILLION)
TABLE 133.REST OF ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 134.REST OF ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035 ($MILLION)
TABLE 135.REST OF ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 136.REST OF ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 137.THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
TABLE 138.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 139.THERMO FISHER SCIENTIFIC INC. PRODUCT SEGMENTS
TABLE 140.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 141.F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 142.F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 143.F. HOFFMANN-LA ROCHE LTD. PRODUCT SEGMENTS
TABLE 144.F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 145.ILLUMINA INC.: KEY EXECUTIVES
TABLE 146.ILLUMINA INC.: COMPANY SNAPSHOT
TABLE 147.ILLUMINA, INC..  PRODUCT SEGMENTS
TABLE 148.ILLUMINA, INC.: PRODUCT PORTFOLIO
TABLE 149.QIAGEN NV.: KEY EXECUTIVES
TABLE 150.QIAGEN NV.: COMPANY SNAPSHOT
TABLE 151.QIAGEN NV. PRODUCT SEGMENT
TABLE 152.QIAGEN NV.: PRODUCT PORTFOLIO
TABLE 153.SYSMEX CORPORATION: KEY EXECUTIVES
TABLE 154.SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 155.SYSMEX CORPORATION: PRODUCT SEGMENT
TABLE 156.SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 157.AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
TABLE 158.AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 159.AGILENT TECHNOLOGIES, INC. PRODUCT SEGMENTS
TABLE 160.AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 161.GUARDANT HEALTH: PRODUCT PORTFOLIO
TABLE 162.DANAHER CORPORATION: KEY EXECUTIVES
TABLE 163.DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 164.DANAHER CORPORATION PRODUCT SEGMENTS
TABLE 165.DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 166.ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 167.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 168.ABBOTT LABORATORIES PRODUCT SEGMENTS
TABLE 169.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 170.LUCENCE HEALTH INC: KEY EXECUTIVES
TABLE 171.LUCENCE HEALTH INC: COMPANY SNAPSHOT
TABLE 172.LUCENCE HEALTH INC: PRODUCT SEGMENTS
TABLE 173.LUCENCE HEALTH INC: PRODUCT PORTFOLIO
TABLE 174.GUARDANT HEALTH: KEY EXECUTIVES
TABLE 175.GUARDANT HEALTH: COMPANY SNAPSHOT
TABLE 176.GUARDANT HEALTH PRODUCT SEGMENTS
TABLE 177.GUARDANT HEALTH: PRODUCT PORTFOLIO
TABLE 178.GUARDANT HEALTH: PRODUCT PORTFOLIO
TABLE 179.LIFESTRANDS GENOMICS PTE. LTD: KEY EXECUTIVES
TABLE 180.LIFESTRANDS GENOMICS PTE. LTD: COMPANY SNAPSHOT
TABLE 181.LIFESTRANDS GENOMICS PTE. LTD PRODUCT SEGMENTS
TABLE 182.LIFESTRANDS GENOMICS PTE. LTD: PRODUCT PORTFOLIO
TABLE 183.ACT GENOMICS: KEY EXECUTIVES
TABLE 184.ACT GENOMICS: COMPANY SNAPSHOT
TABLE 185.ACT GENOMICS: PRODUCT SEGMENTS
TABLE 186.ACT GENOMICS: PRODUCT PORTFOLIO
TABLE 187.SIEMENS HEALTHINEERS AG: KEY EXECUTIVES
TABLE 188.SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 189.SIEMENS HEALTHINEERS AG PRODUCT SEGMENTS
TABLE 190.SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.EXECUTIVE SUMMARY ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET (TAM)
FIGURE 02.EXECUTIVE SUMMARY ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET (SAM)
FIGURE 03.SEGMENTATION OF ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET
FIGURE 04.TOP INVESTMENT POCKETS IN ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET (2023 TO 2033)
FIGURE 05.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06.MODERATE BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE THREAT OF SUBSTITUTION
FIGURE 08.MODERATE THREAT OF NEW ENTRANTS
FIGURE 09.MODERATE COMPETITIVE RIVALRY
FIGURE 10.OPPORTUNITY, RESTRAINT, AND DRIVERS: ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET
FIGURE 11.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035 (%)
FIGURE 12.MARKET SHARE ANALYSIS OF ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY,  2023-2035 (%)
FIGURE 13.MARKET SHARE ANALYSIS OF ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2023-2035 (%)
FIGURE 14.MARKET SHARE ANALYSIS OF ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2023-2035 (%)
FIGURE 15.MARKET SHARE ANALYSIS OF ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2023-2035 (%)
FIGURE 16.MARKET SHARE ANALYSIS OF ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER, BY COUNTRY, 2023-2035 (%)
FIGURE 17.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2023-2035(%)
FIGURE 18.MARKET SHARE ANALYSIS OF ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2035 (%)
FIGURE 19.MARKET SHARE ANALYSIS OF ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR NEXT GENERATION SEQUENCING,  BY COUNTRY, 2023-2035 (%)
FIGURE 20.MARKET SHARE ANALYSIS OF ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2023-2035 (%)
FIGURE 21.MARKET SHARE ANALYSIS OF ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR SPECTROMETRY, BY COUNTRY, 2023-2035 (%)
FIGURE 22.MARKET SHARE ANALYSIS OF ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY (IHC), BY COUNTRY, 2023-2035 (%)
FIGURE 23.MARKET SHARE ANALYSIS OF ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR OTHER, BY COUNTRY, 2023-2035 (%)
FIGURE 24.ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2035(%)
FIGURE 25.MARKET SHARE ANALYSIS OF ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL, BY COUNTRY, 2023-2035 (%)
FIGURE 26.MARKET SHARE ANALYSIS OF ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR OTHER, BY COUNTRY, 2023-2035 (%)
FIGURE 27.MARKET SHARE ANALYSIS OF ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR OTHER, BY COUNTRY, 2023-2035 (%)
FIGURE 28.TOP WINNING STRATEGIES, BY YEAR, 2021-2024*
FIGURE 29.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2024*
FIGURE 30.TOP WINNING STRATEGIES, BY COMPANY, 2021-2024*
FIGURE 31.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 32.COMPETITIVE DASHBOARD
FIGURE 33.COMPETITIVE HEATMAP: ASIA–PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET
FIGURE 34.TOP PLAYER POSITIONING, 2023
FIGURE 35.THERMO FISHER SCIENTIFIC INC.: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 36.THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 37.THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 38.F. HOFFMANN-LA ROCHE LTD.: NET SALES 2021-2023 ($MILLION)
FIGURE 39.F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 40.F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 41.ILLUMINA, INC..: NET SALES, 2021-2023 ($MILLION)
FIGURE 42.ILLUMINA, INC..: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 43.ILLUMINA, INC: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 44.QIAGEN NV.: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 45.QIAGEN NV.: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 46.SYSMEX CORPORATION: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 47.SYSMEX CORPORATION: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 48.SYSMEX CORPORATION: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 49.AGILENT TECHNOLOGIES, INC.: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 50.AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 51.AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 52.DANAHER CORPORATION: NET REVENUE 2021-2023 ($MILLION)
FIGURE 53.DANAHER CORPORATION: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 54.DANAHER CORPORATION: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 55.ABBOTT LABORATORIES: NET SALES, 2021-2023 ($MILLION)
FIGURE 56.ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 57.ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 58.SIEMENS HEALTHINEERS AG: NET SALES, 2021-2023 ($MILLION)
FIGURE 59.SIEMENS HEALTHINEERS AG: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 60.SIEMENS HEALTHINEERS AG: REVENUE SHARE BY REGION, 2023 (%)